- Home
- MYGN vs CCEC Comparison
MYGN vs CCEC Comparison
Compare MYGN & CCEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- CCEC
- Stock Information
- Founded
- MYGN 1991
- CCEC 2007
- Country
- MYGN United States
- CCEC Greece
- Employees
- MYGN N/A
- CCEC N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CCEC Marine Transportation
- Sector
- MYGN Health Care
- CCEC Consumer Discretionary
- Exchange
- MYGN Nasdaq
- CCEC Nasdaq
- Market Cap
- MYGN 1.3B
- CCEC 1.1B
- IPO Year
- MYGN 1995
- CCEC 2007
- Fundamental
- Price
- MYGN $8.80
- CCEC $20.09
- Analyst Decision
- MYGN Hold
- CCEC Buy
- Analyst Count
- MYGN 15
- CCEC 2
- Target Price
- MYGN $20.43
- CCEC $24.00
- AVG Volume (30 Days)
- MYGN 875.3K
- CCEC 12.2K
- Earning Date
- MYGN 05-06-2025
- CCEC 04-29-2025
- Dividend Yield
- MYGN N/A
- CCEC 3.12%
- EPS Growth
- MYGN N/A
- CCEC 20.78
- EPS
- MYGN N/A
- CCEC 2.60
- Revenue
- MYGN $837,600,000.00
- CCEC $369,413,000.00
- Revenue This Year
- MYGN $3.03
- CCEC $19.13
- Revenue Next Year
- MYGN $8.31
- CCEC $20.93
- P/E Ratio
- MYGN N/A
- CCEC $165.30
- Revenue Growth
- MYGN 11.21
- CCEC 2.45
- 52 Week Low
- MYGN $8.53
- CCEC $14.45
- 52 Week High
- MYGN $29.30
- CCEC $20.40
- Technical
- Relative Strength Index (RSI)
- MYGN 27.06
- CCEC N/A
- Support Level
- MYGN $8.53
- CCEC N/A
- Resistance Level
- MYGN $10.30
- CCEC N/A
- Average True Range (ATR)
- MYGN 0.44
- CCEC 0.00
- MACD
- MYGN -0.01
- CCEC 0.00
- Stochastic Oscillator
- MYGN 15.08
- CCEC 0.00
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About CCEC Capital Clean Energy Carriers Corp. Common Share
Capital Clean Energy Carriers Corp is an international shipping company. It is the leading platform of gas carriage solutions with a focus on the energy transition. The company owns 20 high-specification vessels, including 12 latest-generation LNG carriers (LNG/Cs) and eight legacy Neo-Panamax container vessels.